Epigenetic regulator BMI1 promotes fusion-positive rhabdomyosarcoma proliferation and constitutes a novel therapeutic target
Authors:
- Cara E. ShieldsCSCara E. Shields
- Sindhu PotlapalliSPSindhu Potlapalli
- Selma M. Cuya-SmithSCSelma M. Cuya-Smith
- Sarah K. ChappellSCSarah K. Chappell
- Dongdong ChenDCDongdong Chen
- Daniel MartinezDMDaniel Martinez
- Jennifer PogorilerJPJennifer Pogoriler
- Komal S. RathiKRKomal S. Rathi
- Shiv A. PatelSPShiv A. Patel
- John M. MarisJMJohn M. Maris
- Robert W. SchneppRSRobert W. Schnepp
Preprint
Abstract
Rhabdomyosarcoma (RMS) is an aggressive pediatric soft tissue sarcoma that continues to present significant challenges to pediatric oncology. There are two major subtypes of pediatric rhabdomyosarcoma, alveolar and embryonal. Alveolar rhabdomyosarcomas are characterized by the presence of a PAX-FOXO1 fusion protein and termed fusion-positive (FP-RMS); embryonal rhabdomyosarcomas (ERMS) lack these fusions and are termed fusion-negative (FN-RMS). Fusion-positive rhabdomyosarcoma (FP-RMS) harbors PAX-FOXO1 fusion proteins and has a worse overall outcome compared to FN-RMS, underscoring the critical need to identify novel targets for this disease. While fusion proteins remain challenging therapeutic targets, recent studies have begun to reveal the key intersection of PAX-FOXO1 fusion proteins with the malignant epigenome, suggesting that epigenetic proteins may serve as novel targets in FP-RMS. Here, we investigate the contribution of the epigenetic regulator BMI1 to FP-RMS. We examined RNA-seq tumor datasets and determined that BMI1 is robustly expressed in FP-RMS tumors, patient derived xenografts (PDXs), and cell lines. We depleted BMI1 using RNA interference and find that this leads to a marked decrease in cell growth. Next, we used two BMI1 inhibitors, PTC-209 and PTC-028, and showed that BMI1 inhibition decreases cell cycle progression and increases apoptosis in FP-RMS cell lines. In the in vivo setting, targeting BMI1 leads to decreased tumor growth. Mechanistically, we observe that BMI1 inhibition activates the tumor suppressive Hippo pathway. Collectively, these results identify BMI1 as a novel therapeutic vulnerability in FP-RMS and provide a foundation for further investigation of BMI1 in both FP-RMS and additional sarcoma histotypes.Keywords
All Related Versions
- Published version: Molecular Oncology, 15 (8), 2156.
This publication has 50 references indexed in Scilit:
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian CancerPLOS ONE, 2011
- BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcomaOncogene, 2010
- High Expression of the PAX3-FKHR Oncoprotein Is Required to Promote Tumorigenesis of Human MyoblastsThe American Journal of Pathology, 2009
- BMI-1 Promotes Ewing Sarcoma Tumorigenicity Independent ofCDKN2ARepressionCancer Research, 2008
- The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1Oncogene, 2005
- Bmi1, stem cells, and senescence regulationJournal of Clinical Investigation, 2004
- Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcomaOncogene, 2001
- Determination of subcutaneous tumor size in athymic (nude) miceCancer Chemotherapy and Pharmacology, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958